FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry DOI Creative Commons
Manisha Singh, Shruthi Shanmukha, Raghda E. Eldesouki

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 17, 2025

The coronavirus disease 2019 (COVID-19) pandemic has devastated global health and the economy, underscoring urgent need for extensive research into mechanisms of severe acute respiratory syndrome 2 (SARS-CoV-2) viral entry development effective therapeutic interventions. We established a cell line expressing human angiotensin-converting enzyme (ACE2). used it as model pseudotyped using murine leukemia virus (MLV) SARS-CoV-2 spike (S) protein on its surface firefly luciferase reporter. screened an U.S. Food Drug Administration (FDA)-approved compound library inhibiting ACE2-dependent identified several drug-repurposing candidates. 18 drugs drug candidates, including 14 previously reported inhibitors four novel Pyridoxal 5'-phosphate, Dovitinib, Adefovir dipivoxil, Biapenem potently inhibit with inhibitory concentration 50% (IC50) values 57nM, 74 nM, 130 183 respectively. FDA-approved candidate anti-SARS-CoV-2 combination therapy. Our findings contribute to growing body evidence supporting repurposing viable strategy rapidly developing COVID-19 treatments.

Language: Английский

Novel Antiviral Agents: Synthesis, Molecular Modelling Studies and Biological Investigation, 2nd Edition DOI Creative Commons
Simone Brogi

Viruses, Journal Year: 2025, Volume and Issue: 17(5), P. 601 - 601

Published: April 23, 2025

After the success of Special Issue entitled “Novel Antiviral Agents: Synthesis, Molecular Modelling Studies and Biological Investigation” (https://www [...]

Language: Английский

Citations

0
FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry DOI Creative Commons
Manisha Singh, Shruthi Shanmukha, Raghda E. Eldesouki

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 17, 2025

The coronavirus disease 2019 (COVID-19) pandemic has devastated global health and the economy, underscoring urgent need for extensive research into mechanisms of severe acute respiratory syndrome 2 (SARS-CoV-2) viral entry development effective therapeutic interventions. We established a cell line expressing human angiotensin-converting enzyme (ACE2). used it as model pseudotyped using murine leukemia virus (MLV) SARS-CoV-2 spike (S) protein on its surface firefly luciferase reporter. screened an U.S. Food Drug Administration (FDA)-approved compound library inhibiting ACE2-dependent identified several drug-repurposing candidates. 18 drugs drug candidates, including 14 previously reported inhibitors four novel Pyridoxal 5'-phosphate, Dovitinib, Adefovir dipivoxil, Biapenem potently inhibit with inhibitory concentration 50% (IC50) values 57nM, 74 nM, 130 183 respectively. FDA-approved candidate anti-SARS-CoV-2 combination therapy. Our findings contribute to growing body evidence supporting repurposing viable strategy rapidly developing COVID-19 treatments.

Language: Английский

Citations

0